Intec Pharma and Decoy Biosystems Announce Merger Agreement
USA - English
Investigational New Drug Application Filing Expected in 2H 2021
News provided by
Share this article
Share this article
JERUSALEM, March 15, 2021 /PRNewswire/ Intec Pharma Ltd. (NASDAQ: NTEC) ( Intec or the Company ) announced today that it has entered into a definitive agreement for a business combination with Decoy Biosystems, Inc., a privately-held, preclinical-stage biotechnology company developing novel, multi-targeted products that safely prime both innate and adaptive anti-tumor and anti-viral immune responses.
The combined company will advance its immunotherapy platform to battle a variety of tumor types and chronic viral infections. Decoy previously held a pre-IND meeting with the FDA, currently plans to file an IND in the second half of 2021 and to initiate a Phase I clinical trial in 2022 targeting solid tumors and lymphomas.